Although the medications taken by patients could increase tolerogenic DCs, the tolerogenic CD1c+DCs of SLE were observed to be lower than that of controls in this study, which further confirmed that the level of CD1c+DCs were significantly decreased in SLE. The gene discussed is CD1C; the disease is systemic lupus erythematosus.